Edgardo Santos, MD, FACP, FASCO, of Starling Oncology, tells Wade Iams, MD, MSCI, of Tennessee Oncology, what he tells patients to expect over the longer term from subcutaneous amivantamab plus lazertinib in EGFR-mutated advanced non–small cell lung cancer, noting that COPERNICUS is still ongoing.
Wade Iams, MD, MSCI, of Tennessee Oncology, gives Edgardo Santos, MD, FACP, FASCO, of Starling Oncology, an overview of COPERNICUS, a study of subcutaneous amivantamab plus lazertinib in first-line EGFR-mutated advanced non–small cell lung cancer.
Edgardo Santos, MD, FACP, FASCO, of Starling Oncology, describes how he follows patients through the first months of subcutaneous amivantamab plus lazertinib for EGFR-mutated advanced non–small cell lung cancer.
Edgardo Santos, MD, FACP, FASCO, of Starling Oncology, details the orders he places on day 1 for a patient starting subcutaneous amivantamab plus lazertinib for EGFR-mutated advanced non–small cell lung cancer.
Wade Iams, MD, MSCI, of Tennessee Oncology, presents the first clinical scenario in this OncLive My Treatment Approach discussion with Edgardo Santos, MD, FACP, FASCO, of Starling Oncology: a 58-year-old woman who never smoked, with a 6-week history of progressive cough.
Wade Iams, MD, MSCI, of Tennessee Oncology, describes how he opens the first treatment conversation with patients who have EGFR-mutated advanced non–small cell lung cancer and with their families, after Edgardo Santos, MD, FACP, FASCO, of Starling Oncology, notes that grade 3 or higher adverse events were more common with amivantamab plus lazertinib than with osimertinib in MARIPOSA.
Experts compare first-line EGFR-mutated NSCLC regimens, showing why subcutaneous amivantamab+lazertinib and chemo+osimertinib boost survival.
Compare first-line EGFR-mutant NSCLC options, weighing amivantamab–lazertinib vs chemo–osimertinib, plus practical start-up and prevention tips.
Edgardo S. Santos Castillero, MD, discusses MAVERICK, B7-H3 ADC data, and tarlatamab sequencing in SCLC, plus molecular testing in a value-based practice.
Drs. Santos and Lopes provide a forward-looking perspective on the future of HER2-targeted therapy in NSCLC, emphasizing ongoing clinical trials and anticipated paradigm shifts. They discuss the potential for earlier-line use of ADCs, as well as combination strategies that may further improve outcomes.
This section provides practical insights that help oncologists bridge the gap between evidence and practice, enhancing the applicability of HER2-targeted therapies in diverse patient populations.
The discussion turns to mechanisms of resistance to HER2-targeted therapies and the implications for future research and clinical practice. Drs. Santos and Lopes note that, as with other targeted therapies, resistance inevitably develops, necessitating ongoing innovation.
Dr. Santos and Dr. Lopes address the incidence of brain metastases and management of central nervous system (CNS) metastases in patients with HER2-mutated NSCLC, a clinically significant challenge in thoracic oncology.
In this segment, Drs. Santos and Lopes explore treatment sequencing strategies for patients with HER2-mutated NSCLC, a rapidly evolving area of clinical decision-making. The discussion addresses the current positioning of HER2-targeted therapies relative to chemotherapy and immunotherapy, particularly in the first-line setting.
This segment addresses the safety profile and toxicity management of HER2-targeted ADCs, a critical consideration for oncologists integrating these therapies into routine practice.
In this section, the discussion shifts to therapeutic advances in HER2-mutated NSCLC, with a particular focus on antibody-drug conjugates (ADCs) as a transformative treatment modality.
Dr. Edgardo Santos and Dr. Gilberto Lopes introduce the program and establish the clinical relevance of HER2-mutated NSCLC as an emerging target in thoracic oncology.
